You are here: Industry Insights > HFrEF

News List

The Evolving Landscape of Heart Failure Therapies Neeta Ratanghayra
January 31, 2024
Heart failure (HF) is a leading cause of disability worldwide and has a major impact on the global economy and healthcare systems.
Amgen Ends Cardio Alliance with Cytokinetics contractpharma
November 24, 2020
Amgen has terminated its collaboration with Cytokinetics and intends to transition the development and commercialization rights for omecamtiv mecarbil and AMG 594.
AZ’s Forxiga wins EU approval for heart failure pharmatimes
November 06, 2020
AstraZeneca’s Forxiga (dapagliflozin) has been approved in the EU for the treatment of symptomatic heart failure with reduced ejection fraction (HFrEF).
CHMP recommends AstraZeneca’s Forxiga for approval in EU pharmaceutical-technology
October 21, 2020
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended AstraZeneca’s Forxiga (dapagliflozin) for an indication extension of its marketing authorisation in the European Union (EU).
Astrazeneca’s Dapagliflozin gets DCGI nod for treatment of heart failure expresspharma
July 06, 2020
Dapagliflozin (Forxiga) is an SGLT-2 inhibitor that can reduce the risk of cardiovascular death and hospitalisation for heart failure in patients with HFrEF.
Sacubitril-Valsartan Does Not Impact Aortic Stiffness in HFrEF drugs
September 05, 2019
For patients with heart failure and reduced ejection fraction (HFrEF), sacubitril-valsartan does not impact aortic stiffness versus enalapril but is associated with improvements in cardiac structure and function...
Entresto tops mainstay ACE inhibitor in heart failure trial pharmaphorum
December 04, 2018
Two years ago, Novartis launched a big trials programme for its heart failure drug Entresto in the hope of revving up disappointing initial sales, and one of those trials has just delivered positive results.